[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mps-vii\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mps-vii":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100332174","mucopolysaccharidosis-vii-disease-monitoring-program-100332174",false,"NCT03604835","Mucopolysaccharidosis VII Disease Monitoring Program","Mucopolysaccharidosis VII Disease Monitoring Program (MPS VII DMP)","Inclusion Criteria:\n\n* Diagnosis of MPS VII based on laboratory diagnosis, including either enzymatic or mutation analysis.\n* Willing and able to provide written informed consent or, in the case of patients under the age of 18 (or below adult ages as defined by local laws and regulations) or patients \\>18 years of age who have cognitive deficiencies, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the DMP has been explained, and prior to any research-related procedures.\n* Willing to comply with DMP visit schedule.\n\nExclusion Criteria:\n\n* Concurrent participation in other pharmaceutical company-sponsored interventional clinical trial unless approved by Ultragenyx.","ALL",{"count":18,"type":19},50,"ESTIMATED","OBSERVATIONAL","The objectives of this study are to characterize MPS VII disease presentation and progression and assess long-term effectiveness and safety, including hypersensitivity reactions and immunogenicity of vestronidase alfa.",[23,24,25,26],"Mucopolysaccharidosis VII","MPS VII","MPS 7","Sly Syndrome",[28,29,30,31,32],"UX003","Mepsevii","vestronidase alfa-vjbk","vestronidase alfa","recombinant human beta-glucuronidase","RECRUITING","2026-06-10",{"date":36,"type":37},"2026-06-11","ACTUAL",{"date":39,"type":37},"2018-01-29",{"date":41,"type":19},"2032-04",{"name":43,"class":44},"Ultragenyx Pharmaceutical Inc","INDUSTRY",14,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":4,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":62,"locationsCount":4},"100345244","expanded-access-to-mepsevii-100345244","NCT03775174","Expanded Access to Mepsevii","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","EXPANDED_ACCESS","Individual patient expanded access requests may be considered for patients who have no other treatment options",[24,23,26],[56,57],"Expanded Access","Compassionate Use","AVAILABLE","2026-04-06",{"date":61,"type":37},"2026-04-07",{"name":43,"class":44},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100403342","phase-1-pearl-prenatal-enzyme-replacement-therapy-for-lysosomal-storage-disorders-100403342","NCT04532047","PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)","PEARL","Inclusion Criteria:\n\n* Live male or female fetuses at 18 0\u002F7 weeks to 34 6\u002F7 weeks gestation\n* Diagnosis of one of the 8 included LSDs in utero by genetic or enzymatic analyses performed on amniotic fluid, fetal blood, placental tissue, or other samples through chorionic villus sampling (CVS), amniocentesis, cordocentesis, cell free fetal DNA, or other procedures. In the event that parents are identified as genetic carriers for a LSD, diagnostic testing for the fetus would be performed to confirm the diagnosis\n* Pregnant women age 18 years to 50 years, carrying a live male or female fetus at 18 0\u002F7 weeks to 34 6\u002F7 weeks gestation\n* Identified through the above listed means to be carrying a fetus with an LSD.\n* Ability to give written informed consent and comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Fetuses with a concurrent severe structural anomaly\n* Fetuses with an additional pathogenic genetic variant not related to the underlying LSD that contribute a significant risk of morbidity or mortality.\n\nHydrops fetalis will not be an exclusion criterion because ERT has the possibility of significant benefit in this situation.\n\n* Women with one or more significant comorbidities that would preclude fetal intervention including, but not limited to:\n\n  1. inability to complete the procedure secondary to maternal body habitus or placental location\n  2. significant cardiopulmonary disease\n  3. mirror syndrome\n  4. end organ failure\n  5. altered mental status\n  6. placental abruption\n  7. active preterm labor\n  8. preterm premature rupture of membranes.\n* Mother will require therapeutic dosing of anticoagulation within 24 hours prior to or following the intervention.","FEMALE","18 Years","50 Years",{"count":74,"type":19},10,"INTERVENTIONAL",[77],"PHASE1","For detailed information, please view our study website: https:\u002F\u002Fpearltrial.ucsf.edu\u002F\n\nThe investigators aims to determine the the maternal and fetal safety and feasibility of in utero fetal enzyme replacement therapy in fetuses with Lysosomal Storage Diseases.",[80,81,82,83,84,85,86,87,88],"MPS I","MPS II","MPS IVA","MPS VI","Mps VII","Gaucher Disease, Type 2","Gaucher Disease, Type 3","Pompe Disease Infantile-Onset","Wolman Disease","2026-03-14",{"date":91,"type":37},"2026-03-17",{"date":93,"type":37},"2021-07-01",{"date":95,"type":19},"2032-07-31",{"name":97,"class":98},"University of California, San Francisco","OTHER",1]